Replies to post #44951 on Biotech Values

[lumpy9200]

1. If Provenge is as promising as some people think, surely there are ample sources of capital to complete the clinical program.

Dew, I'm hard pressed to think of outside sources for capital. Michael Milken's foundation would be a great source, but they seemingly ignore Provenge or don't believe in it (even after the AC vote).

Honestly, who would pay for compassionate use of Provenge, especially until 9902B results were available?

Best regards,
Geoff

[stuck_holder]

If Provenge is as promising as some people think, surely there are ample sources of capital to complete the clinical program.

if Provenge is safe (and the AC experts unanimously & emphatically said it was via their 17-0 vote, even with knowledge of the CVA side effects in a small number of patients) and that 9901/9902A Provenge trials have demonstrated substantial evidence of efficacy, why should its approval and public availability be delayed? just because some anal retentive and/or conflicted hypocritic doctor wants to protect the turf they feel is being threatened?

as far as ample sources of capital, it appears that there is an equal if not greater source of counterfeit DNDN shares thanks to a corrupted marketplace and regulatory environment to suppress the price/value of the stock. are you now trying to suggest the market is being efficient regarding the valuation of DNDN???

a rather curious commentary i must say.

[walldiver]

Are you implying that the FDA could mandate that Provenge not be approved, and that DNDN should spend tens of millions of dollars each year for a three-year compassionate use program, all the while waiting for marketing approval?

[jellybean]

<<<Are you seriously suggesting that the FDA should approve Provenge merely to facilitate funding >>>

the funding part has been taken care of .....